The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for November 2021 (PDF).
This issue advises clinicians of a new pre-vaccination checklist for the yellow fever vaccine (Stamaril®). The standardised pre-vaccination checklist has been introduced to ensure the yellow fever vaccine is indicated for the intended travel destination and to enable vaccinators to identify existing contraindications or precautions in individuals before vaccination.
Readers are also advised that Emerade® adrenaline auto-injectors have been re-supplied to the market after resolution of an issue that caused some devices to fail to activate and deliver adrenaline. Prescribers are reminded to support safe and effective use with training and advice specific to their prescribed adrenaline auto-injector.
This issue also advises readers of the latest COVID-19 vaccine safety information including regulatory approval for molnupiravir (Lagevrio®) and summaries of Yellow Card reporting noting that Guillain-Barré syndrome (GBS) is now a recognised and very rare side effect for Vaxzevria (previously COVID-19 Vaccine AstraZeneca).
Lastly in this issue is a summary of letters to healthcare professionals in October. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Dapagliflozin no longer indicated in T1DM||NICE Guidance - November 2021 »|